Form 8-K - Current report:
SEC Accession No. 0001641172-25-017185
Filing Date
2025-06-30
Accepted
2025-06-30 17:08:36
Documents
16
Period of Report
2025-06-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 41076
2 EX-10.1 ex10-1.htm EX-10.1 2899
3 GRAPHIC ex10-1_001.jpg GRAPHIC 777458
4 GRAPHIC ex10-1_002.jpg GRAPHIC 438614
5 GRAPHIC ex10-1_003.jpg GRAPHIC 243626
  Complete submission text file 0001641172-25-017185.txt   2220759

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE pcsa-20250624.xsd EX-101.SCH 3059
7 XBRL LABEL FILE pcsa-20250624_lab.xml EX-101.LAB 34239
8 XBRL PRESENTATION FILE pcsa-20250624_pre.xml EX-101.PRE 22388
18 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3683
Mailing Address 7380 COCA COLA DRIVE SUITE 106 HANOVER MD 21076
Business Address 7380 COCA COLA DRIVE SUITE 106 HANOVER MD 21076 443-776-3133
Processa Pharmaceuticals, Inc. (Filer) CIK: 0001533743 (see all company filings)

EIN.: 451539785 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)